Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy

Moo-Yong Rhee,1 Sang Hong Baek,2 Weon Kim,3 Chang Gyu Park,4 Seung Woo Park,5 Byung-Hee Oh,6 Sang-Hyun Kim,7 Jae-Joong Kim,8 Joon-Han Shin,9 Byung-Su Yoo,10 Se-Joong Rim,11 Jong-Won Ha,12 Joon Hyung Doh,13 Youngkeun Ahn,14 Jei Keon Chae,15 Jeong Bae Park,16 Soon-Kil Kim,17 Cheol Ho Kim18

1Cardiovascular Center, Dongguk University Ilsan Hospital, Goyang, South Korea; 2Catholic University of Korea, Seoul St Mary’s Hospital, Seoul; 3Cardiovascular Department of Internal Medicine, Kyung Hee University Medical Center, Seoul; 4Division of Cardiology, Guro Hospital, Korea University College of Medicine, Seoul; 5Division of Cardiology, Samsung Medical Center, Seoul; 6Department of Internal Medicine, Seoul National University Hospital, Seoul; 7Division of Cardiology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul; 8Division of Cardiology, Asan Medical Center, Seoul; 9Division of Cardiology, Ajou University Hospital, Suwon; 10Division of Cardiology, Wonju Severance Christian Hospital, Wonju; 11Division of Cardiology, GangNam Severance Hospital, Seoul; 12Division of Cardiology, Severance Hospital, Seoul; 13Division of Cardiology, Inje University Ilsan Hospital, Goyang, South Korea; 14Department of Cardiology, Chonnam National University Hospital, Gwangju; 15Chonbuk National University Hospital, Jeongju; 16Department of Cardiology, Cheil General Hospital, Dankook University College of Medicine, Seoul; 17Department of Cardiology, Hanyang University Guri Hospital, Guri; 18Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

Correspondence: Cheol Ho Kim
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gumi-ro 173, Bundang-gu, Seongnam-si, Gyeonggi-do 463-707, Republic of Korea
Tel +82 31 787 7001
Fax +82 31 787 4052
Email cheolkim@snu.ac.kr

Background: The study reported here compared the blood pressure (BP)-lowering efficacy of fimasartan alone with that of fimasartan/hydrochlorothiazide (HCTZ) combination in patients whose BP goal was not achieved after 4 weeks of treatment with once-daily fimasartan 60 mg.

Methods: Patients with sitting diastolic blood pressure (siDBP) >90 mmHg with 4 weeks of once-daily fimasartan 60 mg were randomly assigned to receive either once-daily fimasartan 60 mg/HCTZ 12.5 mg or fimasartan 60 mg for 4 weeks. After 4 weeks, the dose was increased from fimasartan 60 mg/HCTZ 12.5 mg to fimasartan 120 mg/HCTZ 12.5 mg or from fimasartan 60 mg to fimasartan 120 mg if siDBP was >90 mmHg.

Results: Of the 263 randomized patients, 256 patients who had available efficacy data were analyzed. The fimasartan/HCTZ treatment group showed a greater reduction of siDBP compared to the fimasartan treatment group at Week 4 (6.88±8.10 mmHg vs 3.38±7.33, P=0.0008), and the effect persisted at Week 8 (8.67±9.39 mmHg vs 5.02±8.27 mmHg, P=0.0023). Reduction of sitting systolic BP in the fimasartan/HCTZ treatment group was also greater than that in the fimasartan treatment group (at Week 4, 10.50±13.76 mmHg vs 5.75±12.18 mmHg, P=0.0069 and, at Week 8, 13.45±15.15 mmHg vs 6.84±13.57 mmHg, P=0.0007). The proportion of patients who achieved a reduction of siDBP ≥10 mmHg from baseline and/or a mean siDBP <90 mmHg after 4 weeks of treatment was higher in the fimasartan/HCTZ treatment group than in the fimasartan treatment group (53.6% vs 39.8%, P=0.0359). The overall incidence of adverse drug reaction was 11.79% with no significant difference between the treatment groups.

Conclusion: The combination treatment of fimasartan and HCTZ achieved better BP control than fimasartan monotherapy, and had comparable safety and tolerance to fimasartan monotherapy.

Keywords: blood pressure, antihypertensive, angiotensin-converting enzyme inhibitor, angiotensin-receptor blocker, angiotensin II type 1 receptor, renin–angiotensin–aldosterone system inhibitor

Introduction
Hypertension is a major independent risk factor for coronary artery disease, stroke, and renal failure. Reducing blood pressure (BP) below the target goal is important to prevent cardiovascular and cerebrovascular events.1 Various kinds of antihypertensive drugs such as diuretics, calcium channel blockers, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin-receptor blockers (ARBs) have been used to lower BP effectively. Fimasartan is a new antihypertensive drug that lowers BP by blocking the angiotensin II type 1 receptor.2 The efficacy of fimasartan in reducing office-measured BP was shown to be greater than that of losartan.3 Maintenance of 24-hour BP reduction by fimasartan was comparable to or slightly better than by
valsartan. The safety profile of fimasartan was also similar to losartan and valsartan.

Despite the availability of various antihypertensive drugs, achieving target BP is difficult in the majority of patients with hypertension, although the control rate is improving. Most patients require a combination of two or more drugs to achieve their target BP because effective BP reduction is difficult with monotherapy. The drug commonly used in combination with ARBs is hydrochlorothiazide (HCTZ). Several studies have demonstrated enhanced BP reduction with combinations of a renin–angiotensin–aldosterone system (RAAS) inhibitor and HCTZ compared to either treatment alone. Because administration of HCTZ alone reduces plasma volume and activates the RAAS, the addition of a RAAS inhibitor to HCTZ may offset the diuretic-induced increase in plasma renin activity and could theoretically attenuate the metabolic effects of HCTZ.

The primary purpose of the study reported here was to compare the BP-lowering efficacy of fimasartan alone with that of fimasartan/HCTZ combination treatment in patients whose BP goal was not achieved after 4 weeks of treatment with once-daily fimasartan 60 mg.

Methods

Patients

Male and female patients aged 18 years and above were enrolled in the study if they met the following criteria: on the screening visit, mean values of two sitting diastolic blood pressure (sDBP) readings had to be <110 mmHg and <120 mmHg if the patient were on antihypertensive medication; if the patient were antihypertensive naïve, the mean values of two sDBP readings had to be ≥90 mmHg and <120 mmHg. Patients were excluded if they had: a mean sitting systolic blood pressure (sSBP) ≥200 mmHg at the screening visit; a difference of sSBP ≥20 mmHg or sDBP ≥10 mmHg between arms; secondary hypertension (ie, renovascular hypertension, endocrinologic disease, and use of hormonal contraceptives or drugs affecting BP); hepatic (aspartate transaminase and alanine transaminase ≥2.0× upper limit of normal) or renal impairment (serum creatinine ≥1.5× upper limit of normal); active hepatitis B or C (including carriers); positive status for HIV; known allergy to the study drugs; a sodium (<133 mmol/L or ≥145 mmol/L) or potassium (<3.5 mmol/L or ≥5.5 mmol/L) electrolyte imbalance; insulin-dependent or uncontrolled diabetes mellitus (glycated hemoglobin [HbA1c] >9%); retinal hemorrhage or exudates within the previous 6 months; drug or alcohol dependency; heart or cerebrovascular disease within the previous 6 months (coronary heart disease, heart failure, significant valvular heart disease, cerebral infarction, or cerebral hemorrhage); active inflammatory gastrointestinal disease in the preceding 12 months or a history of gastrointestinal disease or disease that could interfere with drug absorption; or the presence of a wasting disorder, autoimmune disease, or connective tissue disease. Women who were pregnant, breastfeeding, or those with child-bearing potential who were not sterilized and had no intention of using a contraceptive were also excluded.

Study design

The study was conducted at 18 institutions in Korea as a multicenter, randomized, active-controlled, double-blind, parallel-group, dose-titration trial. The study design was approved by the Korea Food and Drug Administration and the institutional review board of each site. After screening, patients who met the eligibility criteria were given once-daily fimasartan 60 mg for 4 weeks. Patients already receiving antihypertensive therapy discontinued taking their previously prescribed drugs and were directly rolled into once-daily fimasartan 60 mg without a washout period. After 4 weeks of treatment with once-daily fimasartan 60 mg, patients with sDBP ≥90 mmHg were randomly assigned to receive either once-daily fimasartan 60 mg/HCTZ 12.5 mg or fimasartan 60 mg for 4 weeks at a 2:1 ratio by using sealed envelopes with the randomization number. The dose of the study drug was increased to fimasartan 120 mg/HCTZ 12.5 mg or fimasartan 120 mg then maintained for another 4 weeks if the sDBP was still >90 mmHg after 4 weeks of treatment with fimasartan 60 mg/HCTZ 12.5 mg and fimasartan 60 mg. The study-drug dose was maintained in patients whose sDBP was <90 mmHg.

All patients were instructed to take the study drug once daily between 6 am and 10 am for the study duration. Patients were instructed to fast for 12 hours prior to the scheduled visit and to refrain from taking the study medication in the morning before trough BP measurement. At each visit, after at least 5 minutes of rest in a sitting position, sSBP, sDBP, and pulse rate were measured twice with a 1-minute interval between measurements in the same arm using a semiautomated sphygmomanometer (HEM-7080IT [equivalent to 705IT], Omron Corporation, Kyoto, Japan). The average of the two sitting BP measurements was used. All adverse events were evaluated and recorded at each visit.

Efficacy evaluation

This study was designed to compare the antihypertensive efficacy of fimasartan 60 mg/HCTZ 12.5 mg combination...
treatment to that of treatment with fimasartan 60 mg alone in patients who did not achieve the target BP after 4 weeks of treatment with fimasartan 60 mg.

The primary goal of this study was to compare the changes in mean siDBP from the baseline to Week 4 of treatment with the study drug (fimasartan 60 mg/HCTZ 12.5 mg) and the control drug (fimasartan 60 mg) in patients who did not achieve target siDBP after 4 weeks of prior treatment with once-daily fimasartan 60 mg.

The secondary efficacy points were: (1) change of mean siSBP from baseline at 4 and 8 weeks; (2) BP control rate (a proportion of patients who achieved mean siDBP <90 mmHg) and response rate (a proportion of patients who achieved a reduction of siDBP ≥10 mmHg from baseline and/or a mean siDBP <90 mmHg) at 4 and 8 weeks; and (3) change of mean siDBP from baseline at 8 weeks.

Safety evaluation
Safety and tolerability were assessed at each visit by physical examination, direct questioning, and clinical laboratory tests. Blood and urine samples were collected for laboratory tests at baseline, Week 4, and Week 8. Electrocardiography was performed at screening and at the end of the study. All adverse events that occurred during the study and details of their nature, occurrence, and elimination date, duration, severity, significance, and the relationship with the study drug were recorded.

Sample size
To identify the primary hypothesis, we assumed a potential difference of 3 mmHg in mean change of siDBP with a standard deviation of 7.5 mmHg between the two therapies. With a randomization ratio of 2:1 between patients assigned fimasartan 60 mg/HCTZ 12.5 mg and those assigned fimasartan 60 mg, significance level of 5%, and statistical power of 80%, the total number of required subjects was 225 (150 for fimasartan 60 mg/HCTZ 12.5 mg and 75 for fimasartan 60 mg). Allowing for a drop-out rate of 10%, the total number of subjects to be enrolled was estimated to be 250 (167 for the study drug and 83 for the control drug). The number of subjects required for screening, assuming a nonresponder rate of 50%, was estimated to be approximately 500.

Statistical analyses
For efficacy analysis, the intention-to-treat (ITT) analysis set was used for the main analysis while the per-protocol (PP) analysis set was additional. The ITT analysis set included all subjects with efficacy assessment variables for at least one time after randomization. Among the ITT population, the PP analysis set included subjects who completed the study without major or serious protocol violations. If any efficacy assessment variables were missed, they were imputed by the last-observation-carried-forward method. For safety analysis, we included all subjects who received the investigational drug at least once. Subjects who had been enrolled in the study but dropped out before drug administration were excluded. Safety assessment variables were not imputed for missed data.

The changes from baseline in siDBP and siSBP of the two groups at the end of 4 and 8 weeks of treatment were compared by two-sample t-test. In addition, we conducted analysis of covariance for changes of siDBP with baseline siSBP and investigation centers as covariates, and the two treatment groups as the factor. Descriptive statistics for the rates of the responders (siDBP <90 mmHg or siDBP reduction from the baseline ≥10 mmHg) and control subjects (siDBP <90 mmHg) at Weeks 4 and 8 were calculated and the differences between the two groups were analyzed by Pearson’s chi-square.

Adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA; v 13.0) and the percentage of the subjects who experienced any adverse events was determined. The chi-square test was also performed to analyze group differences. The incidence rates are presented by severity and causal relationship with each drug.

Demographic characteristics were compared between the two groups using the t-test or Wilcoxon rank-sum test for continuous variables and the chi-square test or Fisher’s exact test for categorical variables. All data were analyzed using SAS® software (v 9.2; SAS Institute, Cary, NC, USA) and all tests were done at a significance level of 5% using a two-sided test.

Results
Patients’ disposition
Among 654 patients screened, 263 were matched to eligible randomization criteria after 4 weeks of treatment with once-daily fimasartan 60 mg. Of the 263 patients, 175 were assigned to 4 weeks of fimasartan/HCTZ treatment and 88 were assigned to 4 weeks of fimasartan treatment (Figure 1). Among the remaining 391 patients who were not randomized, 233 (59.6%) had a diastolic BP <90 mmHg meeting the exclusion criterion of randomization. Thirty patients discontinued the study after randomization. Of these, six discontinued because of inclusion/exclusion deviation, 14 for consent withdrawal, five for adverse events, two for unsatisfactory responses, and three for other reasons.
Of the 263 patients, 256 were included in the primary efficacy analysis and seven were excluded because of missing efficacy data. There were no significant differences in baseline characteristics between the groups with the exception of the number of smokers (Table 1). The number of smokers was higher in the fimasartan/HCTZ group than in the fimasartan group. The mean age was 54.7 ± 9.1 years. The majority of patients were men (76.6%). Among the prior medication taken by the patients, one had been on a cardiac drug (nicorandil), and another took a peripheral vasodilator (nicametate citrate). The baseline siDBP and siSBP were not different between the treatment groups (P = 0.7032 and 0.4015, respectively).

Efficacy

The means of trough siDBP and siSBP at baseline, Week 4, and Week 8 are presented in Table 2. The reduction of siDBP and siSBP was greater in the fimasartan/HCTZ group than in the fimasartan group. The reduction of siDBP was 6.88±8.10 mmHg in the fimasartan/HCTZ group and 3.38±7.33 mmHg in the fimasartan group at Week 4 (P=0.0008). The difference in siDBP reduction between the treatment groups was −3.35 mmHg (95% confidence interval: −5.39 to −1.32, P=0.0013 by analysis of covariance).

At Week 8, the reduction in siDBP was 8.67±9.39 mmHg in the fimasartan/HCTZ group and 5.02±8.27 mmHg in the fimasartan group (P=0.0023). The reduction in siSBP was 10.50±13.76 mmHg in the fimasartan/HCTZ group and 5.75±12.18 mmHg in the fimasartan group at Week 4 (P=0.0069). At Week 8, the reduction in siSBP was 13.45±15.15 mmHg in the fimasartan/HCTZ group and 6.84±13.57 mmHg in the fimasartan group (P=0.0007).

When the fimasartan dose of both treatment groups was increased to 120 mg in patients who did not achieve the target siDBP (≥90 mmHg) at Week 4, siDBP and siSBP decreased significantly by Week 8 (Table 3). Although there was no statistical significance, the fimasartan/HCTZ group showed greater reduction of siDBP and siSBP compared to the fimasartan group. Reduction in siDBP was 5.72±9.34 mmHg in the fimasartan/HCTZ group and 3.64±6.97 mmHg in the fimasartan group (P=0.1922). Reduction in siSBP was 7.86±15.40 mmHg in the fimasartan/HCTZ group and 4.45±11.45 mmHg in the fimasartan group (P=0.1943).

The responses and control rates are displayed in Figure 2. The response rate at Week 4 was 53.6% (90/168) in the fimasartan/HCTZ group and 39.8% (35/88) in the fimasartan group (P=0.0359). At Week 8, the response rate was 63.1% (106/168) in the fimasartan/HCTZ group and 51.1% (45/88)
Table 1 Baseline characteristics of study population

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Fimasartan/HCTZ (N=168)</th>
<th>Fimasartan (N=88)</th>
<th>Total (N=256)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD)</td>
<td>55.3 (9.40)</td>
<td>53.4 (8.20)</td>
<td>54.7 (9.10)</td>
<td>0.1057*</td>
</tr>
<tr>
<td>Weight (kg), mean (SD)</td>
<td>71.9 (9.70)</td>
<td>71.3 (9.10)</td>
<td>71.7 (9.50)</td>
<td>0.6515*</td>
</tr>
<tr>
<td>Height (cm), mean (SD)</td>
<td>166.8 (6.80)</td>
<td>166.6 (7.90)</td>
<td>166.7 (7.20)</td>
<td>0.8069*</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.4607*</td>
</tr>
<tr>
<td>Male</td>
<td>131 (77.98)</td>
<td>65 (73.86)</td>
<td>196 (76.56)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>37 (22.02)</td>
<td>23 (26.14)</td>
<td>60 (23.44)</td>
<td></td>
</tr>
<tr>
<td>Smoking, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.0095*</td>
</tr>
<tr>
<td>Non-smoker</td>
<td>77 (45.83)</td>
<td>48 (54.55)</td>
<td>125 (48.83)</td>
<td></td>
</tr>
<tr>
<td>Past smoker</td>
<td>44 (26.19)</td>
<td>30 (34.09)</td>
<td>74 (28.91)</td>
<td></td>
</tr>
<tr>
<td>Smoker</td>
<td>47 (27.98)</td>
<td>10 (11.36)</td>
<td>57 (22.27)</td>
<td></td>
</tr>
<tr>
<td>Medication history, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.4739*</td>
</tr>
<tr>
<td>ACE inhibitors or ARBs</td>
<td>87 (51.79)</td>
<td>52 (59.09)</td>
<td>139 (54.30)</td>
<td></td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>71 (42.26)</td>
<td>31 (35.23)</td>
<td>102 (39.84)</td>
<td></td>
</tr>
<tr>
<td>Beta blockers</td>
<td>24 (14.29)</td>
<td>17 (19.32)</td>
<td>41 (16.02)</td>
<td></td>
</tr>
<tr>
<td>Diuretics</td>
<td>16 (9.52)</td>
<td>9 (10.23)</td>
<td>25 (9.77)</td>
<td></td>
</tr>
<tr>
<td>Lipid modifying agents</td>
<td>3 (1.79)</td>
<td>–</td>
<td>3 (1.17)</td>
<td></td>
</tr>
<tr>
<td>Alpha-blockers</td>
<td>1 (0.60)</td>
<td>–</td>
<td>1 (0.39)</td>
<td></td>
</tr>
<tr>
<td>Cardiac drug</td>
<td>–</td>
<td>1 (1.14)</td>
<td>1 (0.39)</td>
<td></td>
</tr>
<tr>
<td>Peripheral vasodilators</td>
<td>1 (0.60)</td>
<td>–</td>
<td>1 (0.39)</td>
<td></td>
</tr>
<tr>
<td>Drinking history, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.0625*</td>
</tr>
<tr>
<td>Non-drinker</td>
<td>39 (23.21)</td>
<td>30 (34.09)</td>
<td>69 (26.95)</td>
<td></td>
</tr>
<tr>
<td>Drinker</td>
<td>129 (76.79)</td>
<td>58 (65.91)</td>
<td>187 (73.05)</td>
<td></td>
</tr>
<tr>
<td>Mean duration of hypertension, years (SD)</td>
<td>6.20 (6.02)</td>
<td>6.59 (5.84)</td>
<td>6.33 (5.95)</td>
<td>0.4465*</td>
</tr>
<tr>
<td>Baseline diastolic blood pressure, mmHg (SD)</td>
<td>96.8 (5.70)</td>
<td>96.5 (5.40)</td>
<td>70.08 (6.00)</td>
<td>0.7078*</td>
</tr>
<tr>
<td>Systolic</td>
<td>150.8 (12.70)</td>
<td>149.4 (11.90)</td>
<td>118.7 (11.80)</td>
<td>0.3994*</td>
</tr>
</tbody>
</table>

Notes: *Difference between treatment groups by two-sample t-test, Wilcoxon rank-sum test, or chi-square test.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; HCTZ, hydrochlorothiazide; SD, standard deviation.

in the fimasartan group, which was not statistically different (P=0.0647). In the PP analysis, the response rate of the fimasartan/HCTZ treatment group was higher than that of the fimasartan treatment group (at Week 4, 55.7% vs 40.2%, P=0.0245 and, at Week 8, 67.1% vs 52.4%, P=0.0280).

Although there was no statistically significant difference, the fimasartan/HCTZ group had a higher control rate at Weeks 4 and 8.

Safety and tolerability

In the safety-analysis population, the incidence of adverse events considered to be at least partly related to the study

Table 2 Means of sitting diastolic and systolic blood pressure at Weeks 4 and 8

<table>
<thead>
<tr>
<th>Visit</th>
<th>Fimasartan/HCTZ (N=168)</th>
<th>Fimasartan (N=88)</th>
<th>Difference in change ± SD</th>
<th>95% confidence interval</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>siDBP (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>96.81±5.65</td>
<td>96.53±5.44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 4</td>
<td>89.93±9.14</td>
<td>93.16±8.87</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change a</td>
<td>–6.88±8.10</td>
<td>–3.38±7.33</td>
<td>–3.50±7.84</td>
<td>–5.53, –1.47</td>
<td>0.0008</td>
</tr>
<tr>
<td>Week 8</td>
<td>88.14±9.65</td>
<td>91.51±9.84</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change a</td>
<td>–8.67±9.39</td>
<td>–5.02±8.27</td>
<td>–3.65±9.02</td>
<td>–5.99, –1.31</td>
<td>0.0023</td>
</tr>
<tr>
<td>siSBP (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>150.77±12.65</td>
<td>149.40±11.87</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 4</td>
<td>140.27±15.55</td>
<td>143.65±14.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change a</td>
<td>–10.50±13.76</td>
<td>–5.75±13.24</td>
<td>–4.75±13.24</td>
<td>–8.18, –1.32</td>
<td>0.0069</td>
</tr>
<tr>
<td>Week 8</td>
<td>137.32±15.90</td>
<td>142.56±16.22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change a</td>
<td>–13.45±15.15</td>
<td>–6.84±13.37</td>
<td>–6.61±14.63</td>
<td>–10.40, –2.82</td>
<td>0.0007</td>
</tr>
</tbody>
</table>

Notes: Data are expressed as mean ± SD. aChange from baseline at Week 4. bChange from baseline at Week 8. P-value by two-sample t-test.
Abbreviations: HCTZ, hydrochlorothiazide; SD, standard deviation; siDBP, sitting diastolic blood pressure; siSBP, sitting systolic blood pressure.
Figure 2 (A) Response and (B) control rate of fimasartan/hydrochlorothiazide (HCTZ) and fimasartan at Weeks 4 and 8 from baseline.
in siSBP. Fimasartan in combination with HCTZ was safe and well tolerated. The incidence of adverse events related to the study-drug treatment was small. There were no serious adverse events related to the study-drug treatment. The most frequent adverse events were headache and dizziness. The incidence did not differ between the treatment groups, and was also comparable to that reported in the previous Phase II and III studies of fimasartan.\textsuperscript{2,3} In terms of biochemical abnormalities, hypokalemia is a commonly associated biochemical abnormality of HCTZ.\textsuperscript{24,25} In the current study, no patient exhibited hypokalemia. It may be the addition of ARB which resulted in favorable effects regarding the biochemical abnormalities associated with HCTZ. Another biochemical abnormality associated with HCTZ is increase in triglyceride,\textsuperscript{26} which appeared in only one patient in the current study. Three patients experienced treatment-related elevation of liver enzyme after escalation of the fimasartan dose to 120 mg/day. The elevated liver enzyme level in two patients returned to normal at the follow-up examination without intervention. The persistent elevation of liver enzyme in the remaining patient at the follow-up examination was concluded to be related to drinking alcohol. The elevation of liver enzyme at the higher dose is consistent with previous studies\textsuperscript{3,23} and improved without intervention.

**Limitations**

A limitation of the current study is that a dose-dependent reduction in BP was not presented, because the study design did not aim at evaluating the dose–response relation. Despite this limitation, dose escalation of fimasartan/HCTZ to 120 mg/12.5 mg or fimasartan 120 mg in patients who did not achieve the target siDBP at Week 4 resulted in significant reductions in siDBP and siSBP at Week 8, indicating a dose-dependent BP-lowering effect.

Another limitation is that the effect of combination treatment with HCTZ 25 mg was not evaluated. Although several studies have shown that 25 mg of HCTZ is more effective in lowering BP, we did not evaluate HCTZ at that dose because of potential biochemical abnormalities such as potassium depletion or uric acid elevation.\textsuperscript{8,9}

**Conclusion**

The results of the current study suggest that combination treatment with fimasartan and HCTZ is effective in patients with hypertension which is not adequately controlled with fimasartan alone. The safety and tolerability of combination fimasartan and HCTZ treatment are comparable to those of fimasartan monotherapy.

**Disclosure**

This research was initiated and financially supported by Boryung Pharmaceutical Co, Ltd, Seoul, Republic of Korea. The sponsor supported the supply of the study drugs, laboratory testing, and data collection and analysis. All authors acted as principal investigators at the study sites, recruited patients, and collected data. The manuscript was prepared, reviewed, and approved by all authors prior to publication. The funding body was not involved in data analysis, data interpretation, or writing up of the results.

Dr Rhee has received lecture honoraria from Pfizer Inc, LG Life Sciences Ltd, and Bayer Korea Ltd, and research grants from Boryung Pharmaceutical Co, Ltd and Dong-A Pharmaceutical Co Ltd.

Dr Kim has received lecture honoraria from GlaxoSmithKline, Hannmi Pharmaceutical Co, Ltd, and research grant from Merck Sharp & Dohme, LG Life Sciences Ltd, and Boryung Pharmaceutical Co, Ltd.

The authors have indicated that they have no other conflicts of interest with regard to the content of this article.

ClinicalTrials.gov identifier: NCT01258673.

**References**


